Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors |
| |
| Authors: | Randa Bittar Élisabeth Aslangul Philippe Giral Lambert Assoumou Marc-Antoine Valantin Olga Kalmykova Marie-Christine Federspiel Corinne Cherfils Dominique Costagliola Dominique Bonnefont-Rousselot |
| |
| Institution: | 1. Unité fonctionnelle de biochimie des maladies métaboliques, service de biochimie métabolique, hôpitaux universitaires Pitié-Salpêtrière – Charles-Foix, Assistance publique–Hôpitaux de Paris, 83, boulevard de l’Hôpital, 75651 Paris cedex 13, France;2. UPMC université Paris 06, UMR_S1166 ICAN, 75013 Paris, France;3. Service de médecine interne, Hôpital Louis-Mourier, Assistance publique–Hôpitaux de Paris, 92701 Colombes, France;4. Université Paris-Descartes, rue de l’École-de-Médecine, 75006 Paris, France;5. Unité de prévention cardiovasculaire, service d’endocrinologie métabolisme, hôpitaux universitaires Pitié-Salpêtrière – Charles-Foix, Assistance publique–Hôpitaux de Paris, 75651 Paris cedex 13, France;6. Sorbonne universités, UPMC université Paris-6, UMR_S 1136, institut Pierre-Louis d’épidémiologie et de santé publique, 75013 Paris, France;7. Inserm, UMR_S 1136, institut Pierre-Louis d’épidémiologie et de santé publique, 75013 Paris, France;8. Service des maladies infectieuses et tropicales, hôpitaux universitaires Pitié-Salpêtrière–Charles-Foix, Assistance publique–Hôpitaux de Paris, 75651 Paris cedex 13, France;9. Inserm U 1022 CNRS UMR 8258, Chimie ParisTech, PSL Research University, unité de technologies chimiques et biologiques pour la santé, faculté de pharmacie, Sorbonne Paris Cité, université Paris-Descartes, 75006 Paris, France |
| |
| Abstract: | BackgroundWe evaluated the effect of 45 days of rosuvastatin or pravastatin treatment on the distribution of HDL subfractions in HIV-1-infected individuals receiving boosted protease inhibitors (PIs) with cardiovascular risk.MethodsThe distribution of HDL subclasses by gradient gel electrophoresis was blindly assessed in 74 HIV-1-infected individuals receiving boosted PIs at baseline and at day 45 of statin treatment, and compared with the distribution obtained in 63 healthy normolipidemic individuals taken as controls.ResultsNo significant modification appeared in HDL distribution between the two arms of statins for the HIV-1-infected individuals. Nevertheless, when compared to controls, HDL subfractions showed a significantly lower HDL2b proportion and significantly higher proportions of HDL2a and HDL3b (P < 0.001).ConclusionNo difference was observed in HDL distribution between pravastatin and rosuvastatin after 45 days treatment, in HIV-1-infected individuals under PIs. Nevertheless, when compared to healthy normolipidemic subjects, HDL distribution is clearly different, with a distribution in HIV-infected individuals under PIs associated with an increased cardiovascular risk. |
| |
| Keywords: | HIV-1 population Rosuvastatin Pravastatin HDL distribution Cardiovascular risk Population VIH-1 Rosuvastatine Pravastatine Distribution des HDL Risque cardiovasculaire |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
